Symptomatic treatment of psycho-organic syndrome whose features are memory loss, attention disorders & lack of drive; cortical myoclonus (alone or in combination); vertigo & associated disorders of balance w/ exception of dizziness of vasomotor or psychic origin in adult. Treatment of dyslexia in combination w/ appropriate measures eg, speech therapy in childn.
Symptomatic treatment of psycho-organic syndrome & treatment of vertigo 2.4-4.8 g/day in 2 or 3 divided doses. Myoclonus of cortical origin Initially 7.2 g/day, increasing by 4.8 g every 3 or 4 days. Max: 24 g in 2 or 3 divided doses. Acute episode: Reduce dose by 1.2 g every 2 days or every 3-4 days for Lance-Adams syndrome. Dyslexia in combination w/ appropriate measures eg, speech therapyChildn & adolescent ≥8 yr 3.2 g/day (8 mL of 20% soln bid or 2 tab of 800 mg).
Severe hemorrhage, patients at risk of bleeding eg, GI ulcer, patients w/ underlying disorders of haemostasis, history of haemorrhagic CVA, undergoing major surgery including dental surgery, using anticoagulants or platelet antiaggregant drugs including low dose ASA. Renal insufficiency. Avoid abrupt discontinuation as may induce myoclonic or generalised seizures in myoclonic patients. May affect ability to drive or operate machinery. Pregnancy & lactation. Elderly.
Sign Out
